Newton, MA – According to filings with the U.S. Securities and Exchange Commission, 4D Path is raising $4,500,000.00 in new funding. Sources indicate as part of senior management President, Rodrigo Navarro played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About 4D Path

4D Path is working towards a solution to effectively bridge the gap between morphological and genetic testing, by integrating cancer diagnostics and precision medicine into a single quantitative digital platform based only on a single hematoxylin and eosin (H&E) stained whole slide biopsy image. Our technology is being developed to predict four major prognostic and therapeutic classes of breast cancer with respect to receptor (ER, PR) and protein (HER2) overexpression status, as well as BRAF/NRAS mutation status of malignant melanomas.

To learn more about 4D Path, visit http://www.4dpath.com/

Contact:
Rodrigo Navarro, President
617-558-0010
https://www.linkedin.com/in/rodrigo-navarro-48218211/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved